Results 221 to 230 of about 101,548 (353)

Super effect or methodological flaw: questioning the glucagon-like peptide-1 receptor agonist cancer narrative. [PDF]

Diabetologia
Maier GA, Rathmann W, Kuß O.
europepmc   +1 more source

Effect of switching from intermittently scanned continuous glucose monitoring to FreeStyle Libre 2 with real‐time continuous glucose monitoring and alert functionality

Journal of Diabetes Investigation, EarlyView.
Transitioning from FSL to FSL2 with rtCGM function improved sensor usage and glycemic control, particularly in patients with Type 1 diabetes. The duration required for improvement in continuous glucose monitoring‐related parameters varied by diabetes type, with early improvements observed in Type 1 diabetes and gradual improvements in Type 2 diabetes ...
Keiji Sugai, Junko Sasaki, Gakuyuki Tomizawa, Ryo Suzuki   +3 more
wiley   +1 more source

Consumer Food Purchases After Glucagon-Like Peptide-1 Receptor Agonist Initiation.

JAMA Netw Open
Sørensen KK, Møller FT, Yazdanfard PDW, Hasselbalch R, Kragholm KH, Andersen MP, Torp-Pedersen C.   +6 more
europepmc   +1 more source

Long-Term Glucagon-Like Peptide 1 Receptor Agonist Use Is Not Associated With Increased Risk of Thyroid Cancer in Adults With Type 2 Diabetes. [PDF]

Diabetes Metab Res Rev
Pollack R, Stokar J.
europepmc   +1 more source

Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double‐blind, randomised, placebo‐controlled cross‐over trial

Diabetes, Obesity and Metabolism, EarlyView.
Luxcia Kugathasan, Michael A. Tsoukas, Massimo Nardone, Vikas S. Sridhar, Marcel H. A. Muskiet, David Z. I. Cherney, Ahmad Haidar, Melissa‐Rosina Pasqua   +7 more
wiley   +1 more source

Efficacy of probiotics (Bifidobacterium bifidum G9‐1) in patients with type 2 diabetes mellitus and chronic kidney disease complicated by constipation: An exploratory, multicenter, open‐label, single‐arm study (BIRDIE study)

Journal of Diabetes Investigation, EarlyView.
Bifidobacterium bifidum G9‐1 improved stool form, defecation frequency, and Quality of Life in patients with type 2 diabetes mellitus and chronic kidney disease complicated by constipation. ABSTRACT Introduction Although constipation is a major complication of type 2 diabetes mellitus and chronic kidney disease, evidence for its treatment in these ...
Fuki Ikeda, Junko Sato, Hidenori Yoshii, Masahiro Sugawara, Hiroaki Satoh, Yukiko Sugawara, Hirotsugu Uzawa, Daisuke Sugimoto, Reina Muto, Yuya Nishida, Hirotaka Watada   +10 more
wiley   +1 more source

Dietary supplement considerations during glucagon-like Peptide-1 receptor agonist treatment: A narrative review. [PDF]

Obes Pillars
Johnson BVB, Milstead M, Kreider R, Jones R.   +3 more
europepmc   +1 more source

Retrospective comparison of the clinical effects of oral semaglutide and SGLT2 inhibitors treatment in patients with type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
This retrospective study compared oral semaglutide and SGLT2 inhibitors in patients with type 2 diabetes over 6 months. Both treatments significantly reduced HbA1c, body weight, and fat mass. Although the reduction in fat mass was comparable, changes in skeletal muscle mass tended to be less favorable with SGLT2 inhibitors than with oral semaglutide ...
Yasuhiro Omori, Ryota Usui, Yuji Yamazaki, Hitoshi Kuwata, Yoshiyuki Hamamoto, Yuichiro Yamada, Yutaka Seino   +6 more
wiley   +1 more source

Periorbital Changes Following Glucagon-Like Peptide-1 Receptor Agonist Use: A Retrospective Cohort Study of Oculofacial Complications and Interventions. [PDF]

Ophthalmic Plast Reconstr Surg
Saffari PS, Davila N, Pradeep T, Wong B, Lee WW.   +4 more
europepmc   +1 more source

Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Diabetes Care, 2017
M. Maiorino, P. Chiodini, G. Bellastella, A. Capuano, K. Esposito, D. Giugliano   +5 more
semanticscholar   +1 more source